Gossamer Bio, Inc. (GOSS) reported topline results for the TORREY Phase 2 study of seralutinib in patients with pulmonary arterial hypertension. In the study, seralutinib significantly improved hemodynamic, biomarker, and right heart structural and functional measures in a heavily treated PAH patient population. Seralutinib was generally well tolerated in the TORREY study.
Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News